The 2022 San Antonio Breast Cancer Symposium (SABCS) reported the updated 5‐year survival results of the ATEMPT trial, which was designed to compare the efficacy of adjuvant T‐DM1 versus paclitaxel plus trastuzumab (TH) for stage I HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.